应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02609 佰泽医疗
未开盘 06-30 16:08:07
3.990
-1.140
-22.22%
最高
5.140
最低
3.900
成交量
3,079万
今开
5.140
昨收
5.130
日振幅
24.17%
总市值
52.59亿
流通市值
52.59亿
总股本
13.18亿
成交额
1.28亿
换手率
2.34%
流通股本
13.18亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股异动 | 佰泽医疗(02609.HK)跌超21% 上周迎来最后一批解禁潮 近期出现两笔大额存仓
智通财经 · 06-30 11:40
港股异动 | 佰泽医疗(02609.HK)跌超21% 上周迎来最后一批解禁潮 近期出现两笔大额存仓
佰泽医疗(02609):采纳2026年股份奖励计划
智通财经 · 06-23
佰泽医疗(02609):采纳2026年股份奖励计划
佰泽医疗(02609):吕超获委任为执行董事
智通财经 · 06-16
佰泽医疗(02609):吕超获委任为执行董事
佰泽医疗(02609)存仓市值总计14.91亿港元 其中股东向中信证券经纪香港存入2.95亿股
智通财经 · 06-12
佰泽医疗(02609)存仓市值总计14.91亿港元 其中股东向中信证券经纪香港存入2.95亿股
佰泽医疗5月无新增发行或股份变动
公告速递 · 06-03
佰泽医疗5月无新增发行或股份变动
格隆汇个股放量排行榜 | 5月25日
格隆汇 · 05-25
格隆汇个股放量排行榜 | 5月25日
佰泽医疗(02609):刘燕辞任副总裁
智通财经 · 05-22
佰泽医疗(02609):刘燕辞任副总裁
佰泽医疗(02609)与微联微通、明悦医疗达成战略合作 将在医疗领域开展全面合作
智通财经 · 05-20
佰泽医疗(02609)与微联微通、明悦医疗达成战略合作 将在医疗领域开展全面合作
佰泽医疗旗下单位与上海微创微联微通健康管理等达成战略合作协议
美股速递 · 05-20
佰泽医疗旗下单位与上海微创微联微通健康管理等达成战略合作协议
佰泽医疗与威联微通、明月医疗达成合作,高值耗材将供应旗下医院
美股速递 · 05-20
佰泽医疗与威联微通、明月医疗达成合作,高值耗材将供应旗下医院
佰泽医疗(02609)附属与美年大健康签署战略合作协议
智通财经 · 05-18
佰泽医疗(02609)附属与美年大健康签署战略合作协议
佰泽医疗集团携手多方 全国推广整合式健康管理体系
美股速递 · 05-18
佰泽医疗集团携手多方 全国推广整合式健康管理体系
佰泽医疗2026年4月股份变动月报表:股本维持不变
公告速递 · 05-04
佰泽医疗2026年4月股份变动月报表:股本维持不变
佰泽医疗2025年收入同比下滑5.8%,肿瘤诊疗与综合服务并进
公告速递 · 04-30
佰泽医疗2025年收入同比下滑5.8%,肿瘤诊疗与综合服务并进
佰泽医疗(2609.HK)盈利稳增筑牢根基,战略升级开启增长新路径
格隆汇 · 04-03
佰泽医疗(2609.HK)盈利稳增筑牢根基,战略升级开启增长新路径
佰泽医疗2026年3月股本维持稳定
公告速递 · 04-02
佰泽医疗2026年3月股本维持稳定
异动解读 | 业绩亏损收窄且经调整利润增长,佰泽医疗盘中大涨5.17%
异动解读 · 04-01
异动解读 | 业绩亏损收窄且经调整利润增长,佰泽医疗盘中大涨5.17%
佰泽医疗(02609)发布2025年度业绩,股东应占亏损1295.7万元,同比收窄3.7%
智通财经 · 03-31
佰泽医疗(02609)发布2025年度业绩,股东应占亏损1295.7万元,同比收窄3.7%
佰泽医疗:向黄山首康医院提供1.88亿元贷款及担保,触发须予披露交易
公告速递 · 03-27
佰泽医疗:向黄山首康医院提供1.88亿元贷款及担保,触发须予披露交易
佰泽医疗(02609.HK)拟3月31日举行董事会会议审批年度业绩
中金财经 · 03-19
佰泽医疗(02609.HK)拟3月31日举行董事会会议审批年度业绩
暂无数据
公司概况
公司名称:
佰泽医疗
所属市场:
SEHK
上市日期:
--
主营业务:
佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务领域提供服务,包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀等,以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02609","market":"HK","secType":"STK","nameCN":"佰泽医疗","latestPrice":3.99,"timestamp":1782806887007,"preClose":5.13,"halted":0,"volume":30794800,"delay":0,"changeRate":-0.22222222222222215,"floatShares":1318000000,"shares":1318000000,"eps":-0.010321,"marketStatus":"未开盘","change":-1.14,"latestTime":"06-30 16:08:07","open":5.14,"high":5.14,"low":3.9,"amount":128424194,"amplitude":0.241715,"askPrice":4.01,"askSize":34800,"bidPrice":3.99,"bidSize":237600,"shortable":3,"etf":0,"ttmEps":-0.011485,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":5.13,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":2.231390826005293,"lotSize":600,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02609/tweets","defaultTab":"tweets","newsList":[{"id":"2647158161","title":"港股异动 | 佰泽医疗(02609.HK)跌超21% 上周迎来最后一批解禁潮 近期出现两笔大额存仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2647158161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647158161?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:40","pubTimestamp":1782790838,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645410839","title":"佰泽医疗(02609):采纳2026年股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2645410839","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645410839?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:00","pubTimestamp":1782219642,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佰泽医疗(02609)发布公告,本公司于2026年6月23日已采纳该计划。该计划仅以现有股份支付,并不涉及发行任何新股份。该计划自采纳日期起计为期十年有效,根据该计划可授予的奖励上限为2000万股股份。受托人将根据董事会之指示,按照计划规则及信托契据从二级市场购买股份,以满足奖励之行使。该计划的目的为(i)表彰若干合资格参与者的贡献,并为彼等提供额外激励以达成绩效目标,以期实现提升本公司价值的目标;及(ii)吸引合适人员以促进本集团的进一步发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1209","02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751094","title":"佰泽医疗(02609):吕超获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751094","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643751094?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:35","pubTimestamp":1781609730,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佰泽医疗(02609)发布公告,赵永凯先生(赵先生)因欲投入更多时间于其他业务,故并无膺选连任,并于股东周年大会结束后退任执行董事。随着赵先生退任,彼亦于股东周年大会结束后不再担任本公司就上市规则第3.05条而言的授权代表。董事会进一步宣布,陈昊阳博士已获委任为授权代表,自2026年6月16日起生效。经股东于股东周年大会上批准后,吕超先生获委任为执行董事,自2026年6月16日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642625847","title":"佰泽医疗(02609)存仓市值总计14.91亿港元 其中股东向中信证券经纪香港存入2.95亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642625847","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642625847?lang=zh_cn&edition=full","pubTime":"2026-06-12 08:13","pubTimestamp":1781223222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,6月11日,佰泽医疗(02609)出现仓位异动,存仓市值总计14.91亿港元,占比22.39%。该公司股东将股票存入中信证券经纪香港2.95亿股,持股比例为22.39%。佰泽医疗截至2025年6月30日止六个月的中期业绩显示,收入5.75亿元(人民币,下同),同比增加0.66%;股东应占亏损2762万元,同比扩大139.18%;每股基本亏损0.02元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","LU1720050803.USD","LU1997245177.USD","BK1521","LU1997245094.SGD","LU2289578879.USD","BK0188","LU1064131003.USD","600030","BK1209","BK0196","LU1655091616.SGD","LU1781817850.SGD","BK0183","LU0405327148.USD","BK1516","LU2495084118.USD","BK0276","LU1064130708.USD","LU1255011170.USD","LU1997244956.HKD","LU0405327494.USD","BK1564","BK1147","BK0012","BK0028","LU1794554557.SGD","02609","LU1328615791.USD","LU2148510915.USD","06030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156826816","title":"佰泽医疗5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1156826816","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156826816?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:47","pubTimestamp":1780476437,"startTime":"0","endTime":"0","summary":"佰泽医疗于2026年6月3日更新披露2026年5月股份变动月报表。报告显示,截至2026年5月31日,公司注册股本未发生变化,维持5,000,000,000股普通股,面值每股0.00001美元,注册股本总额为5万美元。本月已发行股份方面,截至4月底公司已发行普通股1,318,466,823股,无库藏股;经月度调整后,5月底的已发行股份数目维持在1,318,466,823股,公司无新增发行亦无回购注销或库藏股变动。公告由执行董事陈昊阳签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额(万)量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06699","01477","00087","02142","03888","06990","02155","09626","09880","02609","09993","02565","00981","03986","02050","00081","06603","02172","06613","01211","01919","01672","01473","09866","00107","00177","06681","00004","02714","00008","02685","01592","02598","00199","00117","00384","00165","00909","09926","00152","08547","02259","02506","01516","02587","06110","02418","09869","02291","06955"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2637394268","title":"佰泽医疗(02609):刘燕辞任副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2637394268","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637394268?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:35","pubTimestamp":1779438934,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佰泽医疗(02609)发布公告,自2026年5月22日起,刘燕女士已辞任公司副总裁一职,原因是彼有意投入更多时间及精力于彼之其他事务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636812267","title":"佰泽医疗(02609)与微联微通、明悦医疗达成战略合作 将在医疗领域开展全面合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636812267","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636812267?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:40","pubTimestamp":1779266453,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佰泽医疗 发布公告,于2026年5月20日,公司的全资附属公司佰泽医疗投资集团有限公司与上海微创微联微通健康管理有限公司及上海明悦医疗科技有限公司分别签署了战略合作协议。根据战略合作协议,三方将在医疗领域开展全面合作,共同提升医疗服务水准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1209","159891","02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145616300","title":"佰泽医疗旗下单位与上海微创微联微通健康管理等达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1145616300","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145616300?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:38","pubTimestamp":1779266315,"startTime":"0","endTime":"0","summary":"佰泽医疗宣布,其旗下业务单元已与上海微创微联微通健康管理有限公司及其他合作方正式签署战略合作协议。此举标志着公司在拓展健康管理服务网络、整合产业链资源方面迈出了关键一步。通过建立多方位的合作伙伴关系,公司旨在提升其在专业医疗健康服务领域的综合服务能力与市场覆盖范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194490904","title":"佰泽医疗与威联微通、明月医疗达成合作,高值耗材将供应旗下医院","url":"https://stock-news.laohu8.com/highlight/detail?id=1194490904","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194490904?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:36","pubTimestamp":1779266179,"startTime":"0","endTime":"0","summary":"佰泽医疗集团股份有限公司(简称“佰泽医疗”)近日宣布,已与威联微通及明月医疗两家公司签署合作协议。根据协议,后两者将成为佰泽医疗旗下医院的高值医用耗材核心供应商。\n此次合作旨在通过引入优质、稳定的高值耗材供应链,提升佰泽医疗所属医院的临床服务能力与运营效率。高值耗材通常指植入、介入类等价值较高且对医疗安全至关重要的医疗器械。与威联微通和明月医疗的携手,预期将优化佰泽医疗的采购成本结构,并保障其医疗服务的质量与安全标准。\n分析认为,这一供应链布局有助于佰泽医疗巩固其在专科医疗服务领域的竞争力,并为未来的规模化发展奠定坚实的物资基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636025695","title":"佰泽医疗(02609)附属与美年大健康签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2636025695","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636025695?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:35","pubTimestamp":1779093317,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佰泽医疗 发布公告,于2026年5月18日,本公司的全资附属公司佰泽医疗投资集团有限公司与美年大健康产业控股股份有限公司的附属公司,美年大健康产业(集团)有限公司签署了战略合作协议,双方将基于各自优势资源,在全国范围内共同推进“预防筛查-诊疗-康复”一体化的全周期健康管理服务体系构建。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137965960","title":"佰泽医疗集团携手多方 全国推广整合式健康管理体系","url":"https://stock-news.laohu8.com/highlight/detail?id=1137965960","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137965960?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:32","pubTimestamp":1779093142,"startTime":"0","endTime":"0","summary":"佰泽医疗集团股份有限公司宣布,将与多方合作伙伴共同在全国范围内推广其整合式健康管理体系。这一举措旨在将公司创新的健康管理服务模式扩展至更广泛的市场,提升公众健康管理服务的可及性与系统性。通过整合预防、诊断、治疗与康复等环节,该体系致力于为个人及家庭提供全生命周期的连续性健康管理解决方案。此次全国性推广计划,标志着公司在深化业务布局、拓展服务网络方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114360307","title":"佰泽医疗2026年4月股份变动月报表:股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1114360307","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114360307?lang=zh_cn&edition=full","pubTime":"2026-05-04 15:22","pubTimestamp":1777879336,"startTime":"0","endTime":"0","summary":"佰泽医疗于2026年5月4日发布的截至2026年4月30日的月报显示,公司注册股本及已发行股份在本报告期内均保持稳定。报告期内,公司注册股本维持为50,000美元,相当于已发行股份总数为1,318,466,823股,与上月末保持一致。库藏股份数量为零,未发生增减变化。根据公告,公司在报告期内无新增发行、购回或注销股份,亦无相关库存股份的变动。公司在公告中确认其已获得董事会正式授权,遵守所有适用的上市规则、法律以及其他监管规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139029046","title":"佰泽医疗2025年收入同比下滑5.8%,肿瘤诊疗与综合服务并进","url":"https://stock-news.laohu8.com/highlight/detail?id=1139029046","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139029046?lang=zh_cn&edition=full","pubTime":"2026-04-30 22:02","pubTimestamp":1777557742,"startTime":"0","endTime":"0","summary":"佰泽医疗是一家于开曼群岛注册成立并在香港联合交易所有限公司主板挂牌的医疗相关企业,总部位于中国北京市,并在香港设有主要营业地点及股份过户登记处。财务数据方面,综合年报显示,2025年公司实现收入约人民币1,119,849千元,较2024年的1,188,846千元下降约5.8%。在年度战略执行中,佰泽医疗继续深耕肿瘤综合服务,借助多学科诊疗团队与区域优质医疗资源,努力构建从筛查到康复全流程的肿瘤诊疗模式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"佰泽医疗2025年收入同比下滑5.8%,肿瘤诊疗与综合服务并进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624028631","title":"佰泽医疗(2609.HK)盈利稳增筑牢根基,战略升级开启增长新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2624028631","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624028631?lang=zh_cn&edition=full","pubTime":"2026-04-03 11:09","pubTimestamp":1775185774,"startTime":"0","endTime":"0","summary":"经调整净利润达1,790万元,同比增长43.2%","market":"hk","thumbnail":"https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4295479","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1176334012","title":"佰泽医疗2026年3月股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1176334012","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176334012?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:52","pubTimestamp":1775119954,"startTime":"0","endTime":"0","summary":"佰泽医疗集团于2026年4月8日发布2026年3月股份变动月报表,报告期为截至2026年3月31日的当月。公告显示,公司已发行股份及注册股本均保持不变。期末已发行股份总数为1,318,466,823股,与上月一致。报告期内无新增发行、购回或注销股份,亦无库藏股变动。公告同时确认,公司在截至2026年3月末继续符合香港联交所规定的最低公众持股量要求。本次月报由执行董事陈昊阳签署。公司股本结构及上市地位保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124434247","title":"异动解读 | 业绩亏损收窄且经调整利润增长,佰泽医疗盘中大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124434247","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124434247?lang=zh_cn&edition=full","pubTime":"2026-04-01 10:05","pubTimestamp":1775009115,"startTime":"0","endTime":"0","summary":"佰泽医疗今日盘中股价大幅上涨5.17%,引起了市场的广泛关注。消息面上,公司于前一交易日盘后发布了截至2025年12月31日止的年度业绩报告。报告显示,公司股东应占亏损为1295.7万元人民币,较上年同期亏损有所收窄。更为关键的是,公司全年经调整利润达到1790万元人民币,同比大幅增长43.2%。这一积极的财务表现,特别是经调整利润的强劲增长,被市场视为公司运营效率提升和盈利能力改善的信号。尽管公司总收入同比出现小幅下降,但亏损收窄和核心利润指标的大幅改善,增强了投资者对公司未来发展的信心,从而推动了股价在今日盘中的显著上扬。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580295","title":"佰泽医疗(02609)发布2025年度业绩,股东应占亏损1295.7万元,同比收窄3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623580295?lang=zh_cn&edition=full","pubTime":"2026-03-31 22:21","pubTimestamp":1774966919,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佰泽医疗(02609)发布截至2025年12月31日止年度业绩,收入11.2亿元(人民币,下同),同比下降5.8%;公司权益股东应占亏损1295.7万元,同比收窄3.7%;每股基本亏损0.01元。期内收入同比减少约5.8%,主要由于医院业务收入减少人民币3740万元;及供应药品、医疗设备及耗材业务的收入减少人民币2160万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170141864","title":"佰泽医疗:向黄山首康医院提供1.88亿元贷款及担保,触发须予披露交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1170141864","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170141864?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:52","pubTimestamp":1774623131,"startTime":"0","endTime":"0","summary":"佰泽医疗公告,集团根据与安徽首康投资订立的医院管理协议,持续为旗下管理医院——黄山首康医院提供财务支持。截至公告日,集团对该医院的贷款余额及公司担保总额合计1.88亿元,未突破招股章程所设2亿元上限。为防范类似合规事件再次发生,佰泽医疗已向全体董事及管理层发出内部备忘,且计划于2026年4月30日前完成针对上市规则第14章的内部培训,并通过设定2亿元贷款及担保总额上限等措施强化内部控制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620246444","title":"佰泽医疗(02609.HK)拟3月31日举行董事会会议审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620246444","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620246444?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:57","pubTimestamp":1773914222,"startTime":"0","endTime":"0","summary":"格隆汇3月19日丨佰泽医疗(02609.HK)宣布,公司将于2026年3月31日(星期二)举行董事会会议,藉以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止的年度业绩及其刊发以及考虑派发末期股息(如有)的建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260319/32081852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02609","BK1209"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bayzedhealthcare.com","stockEarnings":[{"period":"1week","weight":-0.2528},{"period":"1month","weight":-0.1907},{"period":"3month","weight":-0.125},{"period":"6month","weight":0.0445},{"period":"1year","weight":-0.3533},{"period":"ytd","weight":0.0445}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务领域提供服务,包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀等,以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"佰泽医疗","nameEN":"BAYZED HEALTH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佰泽医疗(02609)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佰泽医疗(02609)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佰泽医疗,02609,佰泽医疗股票,佰泽医疗股票老虎,佰泽医疗股票老虎国际,佰泽医疗行情,佰泽医疗股票行情,佰泽医疗股价,佰泽医疗股市,佰泽医疗股票价格,佰泽医疗股票交易,佰泽医疗股票购买,佰泽医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佰泽医疗(02609)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佰泽医疗(02609)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}